David A. Siegel Allovir, Inc. Call Options Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ALVR
# of Institutions
75Shares Held
46.5MCall Options Held
201KPut Options Held
3.1K-
Eco R1 Capital, LLC San Francisco, CA11.3MShares$9.26 Million0.29% of portfolio
-
Octagon Capital Advisors LP New York, NY9.8MShares$8.04 Million1.63% of portfolio
-
Artal Group S.A. Luxembourg, N46.6MShares$5.41 Million0.3% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.3MShares$2.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.65MShares$2.17 Million0.0% of portfolio
About Allovir, Inc.
- Ticker ALVR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 93,063,400
- Market Cap $76.3M
- Description
- Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...